A Safety Study in Patients With Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label, dose-escalation study to determine the tolerability, safety profile,
and antitumor activity of SGN-40 in patients with CLL. All patients will receive dose
escalation during the first two weeks regardless of cohort designation.